Clinical Trial Detail

NCT ID NCT02626364
Title Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Arog Pharmaceuticals, Inc.
Indications

glioblastoma multiforme

gliosarcoma

Therapies

Crenolanib

Age Groups: adult

Additional content available in CKB BOOST